Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

• Data show long-term efficacy of danicopan plus ravulizumab/eculizumab for continued control of terminal complement, IVH, and cs-EVH in PNH

• Danicopan demonstrated a favorable benefit-risk profile, with a breakthrough hemolysis rate of 6 events per 100 patient-years

Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH: hemoglobin [Hgb] ≤9.5 g/dL and absolute reticulocyte count [ARC] ≥120×109/L). In the phase 3 ALPHA trial, participants received oral factor D inhibitor danicopan (150 mg 3 times daily) or placebo plus ravulizumab or eculizumab during the 12-week, double-blind treatment period (TP) 1; those receiving placebo switched to danicopan during the subsequent 12-week, open-label TP2 and continued during the 2-year long-term extension (LTE). There were 86 participants randomized in the study, of whom 82 entered TP2 and 80 entered LTE. The primary endpoint was met, with Hgb improvements from baseline at week 12 (Wk12) (LS mean change: 2.8 g/dL) with danicopan. For participants switching from placebo to danicopan at Wk12, improvements in mean Hgb were observed at Wk24. Similar trends were observed for the proportion of participants with ≥2 g/dL Hgb increase, ARC, proportion of participants achieving transfusion avoidance, and Functional Assessment of Chronic Illness Therapy-Fatigue scale scores. Improvements were maintained up to week 72. No new safety signals were observed. The breakthrough hemolysis rate was 6 events per 100 patient-years. These long-term data demonstrate sustained efficacy and safety of danicopan plus ravulizumab/eculizumab for continued control of terminal complement activity, intravascular hemolysis, and cs-EVH in PNH. Registration: Clinicaltrials.gov, NCT04469465.